Orforglipron (Foundayo) Launch and Regulatory Progress
The FDA approved orforglipron for obesity, and the company launched it in the U.S. during Q2 2026, with submissions for type 2 diabetes in the U.S., EU, and Japan.
At the archive date, ELI LILLY & Co was expected to release its Q3 2026 10-Q filing on October 29, 2026. Last quarter: Lilly's Q2 FY2026 results were driven by incretin demand, with Mounjaro and Zepbound fueling revenue growth, while heavy investment in acquisitions and pipeline expansion weighed on profitability.
EPS Estimate
$9.88
Revenue Estimate
$22.4B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the LLY page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
The FDA approved orforglipron for obesity, and the company launched it in the U.S. during Q2 2026, with submissions for type 2 diabetes in the U.S., EU, and Japan.
Mounjaro and Zepbound accounted for 65% of total revenue in H1 FY2026, with volume growth partially offset by lower realized prices, especially in China after Mounjaro’s NRDL listing.
Gross margin as a percentage of revenue increased 1.5 percentage points to 85.8%, driven by improved production costs and favorable product mix.
Revenue
$22.97B
+47.67% YoY
EPS (Diluted)
$7.94
+26.23% YoY
Add LLY to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.